In drug development, as in life, there’s often a high stakes race against time and complexity. Much like the legendary railroad engineers in the early 1900s, industry teams often charge full steam ahead in the quest towards developing novel therapies.

The thrill of progress continues to propel us forward, especially in the rapidly evolving world of cancer immunotherapy.

Checkpoint blockade therapies have certainly opened new avenues, empowering the immune system to recognise and fight cancer.

Despite their initial success, much like unexpected obstacles on a winding rail track, resistance and immune escape are persistent challenges over time.

Research teams are accelerating efforts to outmanoeuvre these barriers, exploring ADCs, multi-targeted combinations, as well as bispecific and trispecific antibodies.

In this article, we’ll examine new data on some these strategic efforts and the avenues emerging from the recent SITC presentations – advances which could either redefine the checkpoint blockade landscape for the future and keep our train moving steadily on the rails or end up in the graveyard known as dog drug heaven…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by